98%
921
2 minutes
20
ADHD is highly comorbid with Delayed Sleep Phase Syndrome (DSPS). Both are associated with obesity and diabetes, which can be caused by long-term dysregulations of appetite and glucose metabolism. This study explores hormones involved in these processes and the effects of chronotherapeutic interventions in a small sample of adults with ADHD and DSPS. Exploratory, secondary analysis of data from the PhASE study, a three-armed randomized clinical trial, are presented, including 37 adults (18-53 years) with ADHD and DSPS receiving three weeks of 0.5 mg/day (1) placebo, (2) melatonin, or (3) melatonin plus 30 minutes of bright light therapy (BLT). Leptin (appetite-suppressing), ghrelin (appetite-stimulating), insulin, insulin-like growth factor-1 (IGF-1), and glucose were measured from blood collected at 08:00 hours. Salivary cortisol was collected during the first 30 minutes after awakening and self-reported appetite was assessed. Baseline leptin and IGF-1 levels were higher than reference ranges, and ghrelin and cortisol levels were lower, while insulin and glucose were normal. Melatonin treatment decreased leptin and insulin. Other outcomes remained unchanged and melatonin + BLT had no effects. Due to the small sample size and exploratory nature of the study, results should be interpreted with caution. Overall, these results show no strong indications for dysregulation of appetite and glucose metabolism to suggest high risk of obesity and diabetes in this small sample of adults with ADHD and DSPS. However, baseline appetite was suppressed, likely because measurements took place in the early morning which could be considered the biological night for this study population. Melatonin treatment seemed to cause subtle changes in appetite-regulating hormones suggesting increased appetite. Chronotherapeutic treatment may affect appetite-regulating hormones by advancing the biological rhythm and/or altering eating behaviors, but this remains to be investigated in larger samples using detailed food diaries.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/10870547241285160 | DOI Listing |
J Epidemiol Community Health
September 2025
Nepean Medical School, The University of Sydney, Kingswood, New South Wales, Australia
Background: Children and young adults with attention-deficit/hyperactivity disorder (ADHD) may be at increased risk of criminal offending. This study examines the risk of first-time and repeat offending among individuals with ADHD and potential effect of stimulant medication.
Methods: A population-based, data linkage cohort study of individuals born in New South Wales, Australia between 1990 and 2005 and followed until May 2016.
Br J Psychiatry
September 2025
Segunda Cátedra de Farmacología, Facultad de Medicina, Universidad de Buenos Aires, Argentina.
Objective: Methylphenidate is effective in reducing ADHD symptoms in the short term, but long-term benefits are inconsistent, possibly due to the development of tolerance. Moreover, little is known about its sustained effects on brain functional connectivity. We examined whether a 4-month methylphenidate treatment leads to sustained alterations in resting-state functional connectivity, and whether acute brain responses to methylphenidate decrease after treatment, as a potential marker of neurobiological tolerance.
View Article and Find Full Text PDFBr J Psychiatry
September 2025
Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Eur Psychiatry
September 2025
Centre of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.